HOTH News and Press, Hoth Therapeutics Inc. From 01/18/24

Hoth Therapeutics Announces it Received FDA Approval to Expand HT-001 Clinical Trial to Treat Severely Ill Patients PR Newswire Patients will be able to enroll in trial at any time and regardless of failure from other therapeutics NEW YORK , Jan. 18, 2024 ...

2023-12-27 10:00:36 ET More on Health Care Select Sector SPDR XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Healthcare and utilities could perform better in 2024 - analyst Arcus, Bristol-Myers, ...

Hoth Therapeutics Announces Expansion of FDA Cleared First-In-Human Clinical Trial For Cancer Patients of HT-001 at University of Miami PR Newswire NEW YORK , Dec. 27, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH ), a patient-focused biopharmaceutical c...

Hoth Therapeutics Announces it Has Successfully Completed Manufacturing of its Cancer fighting HT-KIT for IND-Enabling Studies PR Newswire NEW YORK , Dec. 5, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical com...

2023-11-14 09:45:28 ET Hoth Therapeutics ( NASDAQ: HOTH ) stock jumped 6% in early trading after the company said it received positive feedback from the FDA on the proposed development plan for its oncology drug candidate HT-KIT. Hoth said in a statement that it met with the...

Hoth Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Development of Hoth's Cancer Fighting HT-KIT PR Newswire Hoth intends to continue development under Orphan Drug Designation NEW YORK , Nov. 14, 2023 /PRNewswire/ -- Ho...

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...

Hoth Therapeutics Inc. (HOTH) is expected to report for Q1 2024

2023-10-26 13:48:39 ET More on BioVie, Cognition, etc. BioVie: Bullish Signals From Blinded Data Presentation (Rating Upgrade) Prothena: Switching From 'Hold' To 'Buy' On Lead Alzheimer's Drug Promise BioVie: Well-Powered Phase 3 Trial In Alzheimer's Could Greatly Be...

Hoth Therapeutics Announces Merveille.ai Artificial intelligence Initiative for Drug Discovery PR Newswire The new wholly owned subsidiary will screen for rare disease therapeutics. NEW YORK , Oct. 5, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NAS...